RefleXion Medical has developed an innovative approach to cancer treatment through its SCINTIX® biology-guided radiotherapy technology. This system utilizes radiopharmaceuticals that cancer cells absorb, creating a biological signal that the RefleXion X1 platform can detect. By integrating positron emission tomography (PET) data with radiotherapy, SCINTIX therapy allows for real-time tracking and targeting of tumors, even those that are in motion. This capability is particularly beneficial for treating lung and bone tumors, as it enables the delivery of high doses of radiation directly to the tumor while minimizing exposure to surrounding healthy tissues.

The SCINTIX therapy represents a significant advancement in the field of oncology, especially for patients with advanced-stage cancers who previously had limited treatment options. By allowing for the combination of SCINTIX therapy with other treatment modalities such as chemotherapy and immunotherapy, RefleXion aims to enhance patient outcomes. The technology has received recognition from the Centers for Medicare and Medicaid Services (CMS), which established new reimbursement codes to facilitate access to this groundbreaking therapy, thereby addressing financial barriers to its adoption in clinical settings.

United States

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

RefleXion

Company Details